bioAffinity’s CyPath Lung Test Takes Center Stage in SAB Webinar

Event summary

  • bioAffinity Technologies’ CyPath Lung test to be featured in a Society for Advanced Bronchoscopy webinar on June 16, 2026.
  • Panel includes pulmonologists, oncologists, and thoracic surgeons discussing the test’s role in early lung cancer detection.
  • CyPath Lung demonstrated 92% sensitivity and 87% specificity in detecting lung cancer in high-risk patients with small nodules.
  • Test aims to reduce unnecessary invasive procedures by providing high negative predictive value (99%).

The big picture

The webinar underscores the growing importance of noninvasive diagnostics in early lung cancer detection, aligning with broader industry trends toward minimizing invasive procedures. bioAffinity’s CyPath Lung test addresses a critical gap in managing indeterminate lung nodules, particularly in high-risk patients. The collaboration with the Society for Advanced Bronchoscopy highlights the test’s expanding role in multidisciplinary clinical settings, potentially influencing future diagnostic standards.

What we're watching

Adoption Pace
How quickly CyPath Lung will be integrated into clinical practices following the webinar.
Regulatory Clarity
Whether the test will secure broader regulatory approval beyond its current Laboratory Developed Test status.
Market Differentiation
The extent to which CyPath Lung can distinguish itself in a competitive landscape of lung cancer diagnostics.

Related topics

Biotechnology